newsfilter
← Latest News
Business Wire·

Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting

Includes presentation of additional late-breaking Phase 3 ATHENA-MONO trial data as complement to previously announced topline data Clovis Oncology, Inc. (NASDAQ:CLVS), announced today that seven abstracts from the company's pipeline, including late-